These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

329 related items for PubMed ID: 16638876

  • 1. Roles of nitric oxide synthase inhibition and vascular endothelial growth factor receptor-2 inhibition on vascular morphology and function in an in vivo model of pancreatic cancer.
    Camp ER, Yang A, Liu W, Fan F, Somcio R, Hicklin DJ, Ellis LM.
    Clin Cancer Res; 2006 Apr 15; 12(8):2628-33. PubMed ID: 16638876
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin.
    Lamszus K, Brockmann MA, Eckerich C, Bohlen P, May C, Mangold U, Fillbrandt R, Westphal M.
    Clin Cancer Res; 2005 Jul 01; 11(13):4934-40. PubMed ID: 16000592
    [Abstract] [Full Text] [Related]

  • 3. Regional effects of an antivascular endothelial growth factor receptor monoclonal antibody on receptor phosphorylation and apoptosis in human 253J B-V bladder cancer xenografts.
    Davis DW, Inoue K, Dinney CP, Hicklin DJ, Abbruzzese JL, McConkey DJ.
    Cancer Res; 2004 Jul 01; 64(13):4601-10. PubMed ID: 15231672
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2.
    Kunkel P, Ulbricht U, Bohlen P, Brockmann MA, Fillbrandt R, Stavrou D, Westphal M, Lamszus K.
    Cancer Res; 2001 Sep 15; 61(18):6624-8. PubMed ID: 11559524
    [Abstract] [Full Text] [Related]

  • 5. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases.
    Bruns CJ, Liu W, Davis DW, Shaheen RM, McConkey DJ, Wilson MR, Bucana CD, Hicklin DJ, Ellis LM.
    Cancer; 2000 Aug 01; 89(3):488-99. PubMed ID: 10931447
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis.
    Zhang L, Yu D, Hicklin DJ, Hannay JA, Ellis LM, Pollock RE.
    Cancer Res; 2002 Apr 01; 62(7):2034-42. PubMed ID: 11929822
    [Abstract] [Full Text] [Related]

  • 10. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
    Timke C, Zieher H, Roth A, Hauser K, Lipson KE, Weber KJ, Debus J, Abdollahi A, Huber PE.
    Clin Cancer Res; 2008 Apr 01; 14(7):2210-9. PubMed ID: 18381963
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668.
    Davis DW, Takamori R, Raut CP, Xiong HQ, Herbst RS, Stadler WM, Heymach JV, Demetri GD, Rashid A, Shen Y, Wen S, Abbruzzese JL, McConkey DJ.
    Clin Cancer Res; 2005 Jan 15; 11(2 Pt 1):678-89. PubMed ID: 15701856
    [Abstract] [Full Text] [Related]

  • 13. Effect of cyclooxygenase and nitric oxide synthase inhibitors on tumor growth in mouse tumor models with and without cancer cachexia related to prostanoids.
    Cahlin C, Gelin J, Delbro D, Lönnroth C, Doi C, Lundholm K.
    Cancer Res; 2000 Mar 15; 60(6):1742-9. PubMed ID: 10749148
    [Abstract] [Full Text] [Related]

  • 14. Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer.
    Wu Y, Zhong Z, Huber J, Bassi R, Finnerty B, Corcoran E, Li H, Navarro E, Balderes P, Jimenez X, Koo H, Mangalampalli VR, Ludwig DL, Tonra JR, Hicklin DJ.
    Clin Cancer Res; 2006 Nov 01; 12(21):6573-84. PubMed ID: 17085673
    [Abstract] [Full Text] [Related]

  • 15. Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth.
    Laakkonen P, Waltari M, Holopainen T, Takahashi T, Pytowski B, Steiner P, Hicklin D, Persaud K, Tonra JR, Witte L, Alitalo K.
    Cancer Res; 2007 Jan 15; 67(2):593-9. PubMed ID: 17234768
    [Abstract] [Full Text] [Related]

  • 16. [Inhibition of bladder cancer cell growth and angiogenesis by co-blockage of vascular endothelial growth factor and its receptor KDR].
    Chen XL, Liu LC, Xu ZG, Li Z, Li RW, Gao RJ, Wang S, Zhang M, Guo H.
    Zhonghua Zhong Liu Za Zhi; 2008 Aug 15; 30(8):578-82. PubMed ID: 19102933
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Vascular endothelial growth factor-trap suppresses tumorigenicity of multiple pancreatic cancer cell lines.
    Fukasawa M, Korc M.
    Clin Cancer Res; 2004 May 15; 10(10):3327-32. PubMed ID: 15161686
    [Abstract] [Full Text] [Related]

  • 20. Effect of Src kinase inhibition on metastasis and tumor angiogenesis in human pancreatic cancer.
    Ischenko I, Guba M, Yezhelyev M, Papyan A, Schmid G, Green T, Fennell M, Jauch KW, Bruns CJ.
    Angiogenesis; 2007 May 15; 10(3):167-82. PubMed ID: 17486419
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.